AR091237A1 - Composiciones que comprenden un aptamero anti factor de crecimiento derivado de plaquetas (anti-pdgf) y un antagonista de factor de crecimiento de endotelio vascular (vegf) - Google Patents

Composiciones que comprenden un aptamero anti factor de crecimiento derivado de plaquetas (anti-pdgf) y un antagonista de factor de crecimiento de endotelio vascular (vegf)

Info

Publication number
AR091237A1
AR091237A1 ARP130101931A AR091237A1 AR 091237 A1 AR091237 A1 AR 091237A1 AR P130101931 A ARP130101931 A AR P130101931A AR 091237 A1 AR091237 A1 AR 091237A1
Authority
AR
Argentina
Prior art keywords
growth
compositions
factor
pdgf
vegf
Prior art date
Application number
Other languages
English (en)
Inventor
Everett Richard
Seon Chang Byeong
Original Assignee
Ophthotech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ophthotech Corp filed Critical Ophthotech Corp
Publication of AR091237A1 publication Critical patent/AR091237A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Composiciones que comprenden un aptámero anti factor de crecimiento derivado de plaqueta (anti-PDGF) y un antagonista de factor de crecimiento del endotelio vascular (VEGF). En algunas formas de realización, las composiciones de la presente son útiles para el tratamiento y prevención de enfermedades oftalmológicas.
ARP130101931 2012-06-01 2013-05-31 Composiciones que comprenden un aptamero anti factor de crecimiento derivado de plaquetas (anti-pdgf) y un antagonista de factor de crecimiento de endotelio vascular (vegf) AR091237A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261654672P 2012-06-01 2012-06-01
US201361778208P 2013-03-12 2013-03-12

Publications (1)

Publication Number Publication Date
AR091237A1 true AR091237A1 (es) 2015-01-21

Family

ID=49674074

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130101931 AR091237A1 (es) 2012-06-01 2013-05-31 Composiciones que comprenden un aptamero anti factor de crecimiento derivado de plaquetas (anti-pdgf) y un antagonista de factor de crecimiento de endotelio vascular (vegf)

Country Status (18)

Country Link
US (1) US20150182623A1 (es)
EP (1) EP2854844A4 (es)
JP (1) JP2015519373A (es)
KR (1) KR20150033620A (es)
CN (1) CN104619335A (es)
AR (1) AR091237A1 (es)
AU (1) AU2013267310A1 (es)
CA (1) CA2874412A1 (es)
CL (1) CL2014003233A1 (es)
CO (1) CO7240393A2 (es)
EA (1) EA201492289A1 (es)
HK (1) HK1207983A1 (es)
IL (1) IL235797A0 (es)
MX (1) MX2014014445A (es)
PH (1) PH12014502577A1 (es)
SG (1) SG11201407981RA (es)
TW (1) TW201400122A (es)
WO (1) WO2013181495A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014286996A1 (en) * 2013-07-12 2016-01-07 Iveric Bio, Inc. Methods for treating or preventing ophthalmological conditions
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CN106852125A (zh) * 2014-08-11 2017-06-13 奥普索特克公司 用于治疗或预防眼科病的方法
CN105435221B (zh) * 2014-09-22 2021-09-28 正大天晴药业集团股份有限公司 一种针对血管内皮生长因子的人源化抗体的药物组合物
CN107206080B (zh) 2015-01-28 2022-07-08 辉瑞公司 稳定的水性抗血管内皮细胞生长因子(vegf)抗体制剂
CN105806830B (zh) * 2015-12-10 2019-01-29 北京联众泰克科技有限公司 一种稳定的hrp酶促化学发光底物液、其制备方法及应用
CN108712911A (zh) 2015-12-30 2018-10-26 科达制药股份有限公司 抗体及其缀合物
JP6953433B2 (ja) * 2016-01-26 2021-10-27 フォーマイコン アーゲーＦｏｒｍｙｃｏｎ Ａｇ Ｖｅｇｆアンタゴニストを含む液体医薬組成物および同医薬組成物を含有する充填済みシリンジ
CN108602879A (zh) * 2016-02-04 2018-09-28 倪劲松 用于治疗疾病的抗体-药物协同作用技术
CN108718522A (zh) * 2016-02-23 2018-10-30 赛森生物股份有限公司 Il-6拮抗剂制剂及其用途
JP7116059B2 (ja) * 2016-11-21 2022-08-09 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド アフリベルセプト製剤及びその使用
KR101861163B1 (ko) 2017-04-26 2018-05-25 삼천당제약주식회사 안과용 약학 조성물
KR20200089282A (ko) * 2017-11-20 2020-07-24 저스트-에보텍 바이오로직스, 아이엔씨. 등장화제로서 라이신 염을 함유하는 아플리베르셉트 제제 및 그것의 용도
WO2019210097A1 (en) * 2018-04-25 2019-10-31 Vitrisa Therapeutics, Inc. Aptamers with stability, potency or half-life for enhanced safety and efficacy
CN112739323A (zh) 2018-05-10 2021-04-30 瑞泽恩制药公司 含有高浓度vegf受体融合蛋白的制剂
WO2020087003A1 (en) * 2018-10-26 2020-04-30 Amgen Inc. Formulations comprising a tris buffer and a protein
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021125852A1 (ko) * 2019-12-17 2021-06-24 주식회사 프로젠 신규 주사제 제형
CN115066262A (zh) * 2020-03-04 2022-09-16 上海复宏汉霖生物技术股份有限公司 一种包含贝伐珠单抗的药物配制剂
JP2023535933A (ja) * 2020-07-24 2023-08-22 パンジェン バイオテック インコーポレイテッド 眼科用液状組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3168304A1 (en) * 2003-08-27 2017-05-17 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
WO2005110374A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
CN101478949A (zh) * 2006-06-16 2009-07-08 瑞泽恩制药公司 适合玻璃体内施用的vegf拮抗剂的制剂
CA2760687A1 (en) * 2009-05-01 2010-11-04 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
PE20140229A1 (es) * 2010-08-26 2014-03-27 Abbvie Inc Inmunoglobulinas con dominio variable dual y usos de las mismas

Also Published As

Publication number Publication date
IL235797A0 (en) 2015-01-29
HK1207983A1 (en) 2016-02-19
CN104619335A (zh) 2015-05-13
CO7240393A2 (es) 2015-04-17
WO2013181495A3 (en) 2014-02-13
CL2014003233A1 (es) 2015-06-19
KR20150033620A (ko) 2015-04-01
US20150182623A1 (en) 2015-07-02
AU2013267310A1 (en) 2014-12-11
TW201400122A (zh) 2014-01-01
EP2854844A4 (en) 2016-11-23
EP2854844A2 (en) 2015-04-08
EA201492289A1 (ru) 2015-05-29
SG11201407981RA (en) 2015-01-29
PH12014502577A1 (en) 2015-01-21
CA2874412A1 (en) 2013-12-05
MX2014014445A (es) 2015-08-14
JP2015519373A (ja) 2015-07-09
WO2013181495A2 (en) 2013-12-05

Similar Documents

Publication Publication Date Title
AR091237A1 (es) Composiciones que comprenden un aptamero anti factor de crecimiento derivado de plaquetas (anti-pdgf) y un antagonista de factor de crecimiento de endotelio vascular (vegf)
CO2017004715A2 (es) Métodos y formulaciones para tratar enfermedades vasculares de los ojos
NI201600071A (es) Compuestos de inhibidor de autotaxina
ECSP17018120A (es) Triazolopirazinonas como inhibidores de pde1
CL2015000061A1 (es) Anticuerpos biespecíficos anti-vegf/anti-ang-2 y su utilización en el tratamiento de enfermedades vasculares oculares
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
GT201600007A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
CL2016000055A1 (es) Métodos para tratar o prevenir afecciones oftalmológicas
CR20150386A (es) Composiciones de nanoparticulas de albumina y paclitaxel
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
DOP2017000254A (es) Imidazopirazinonas como inhibidores de pde1
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CO7020876A2 (es) Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas
MX366317B (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
UY36171A (es) Derivados heteroaromáticos bicíclicos fusionados como inhibidores de quinasa
CY1121000T1 (el) Sirna και χρηση αυτου σε μεθοδους και συνθεσεις για την θεραπεια ή/και προληψη οφθαλμικων καταστασεων
CY1121787T1 (el) Sirna και χρηση αυτων σε μεθοδους και συνθεσεις για τη θεραπεια ή/και προληψη οφθαλμικων καταστασεων
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
CU20160151A7 (es) 2-AMIN0-6-METI L-4,4a, 5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
MX2017005975A (es) Anticuerpos anti factor de crecimiento derivado de plaquetas b (pdgf-b) y metodos de uso.
EP3060259A4 (en) Methods of treating or preventing vascular diseases of the retina
ECSP16061208A (es) Quinazolin-thf-aminas como inhibidores de pde1
DOP2016000263A (es) Quinazolin-thf-aminas halogenadas como inhibidores de pde1
ECSP16071574A (es) Hexahidrofuropirroles como inhibidores de pde1
DK3386509T3 (da) Anvendelse af cabergolin til behandling af øjensygdomme forårsaget af forhøjede niveauer af vaskulær endotelvækstfaktor

Legal Events

Date Code Title Description
FB Suspension of granting procedure